Pacira BioSciences, Inc. reported $168 million in sales and $140 million in operating loss for the quarter ending September 30, 2024, which was below both Wall Street’s expectations and management’s guidance.
Pacira BioSciences Explains and Is Optimistic
Subscribe to continue reading
- Unlimited access to our content and archive
- Exclusive access to our newsletter
- Join the Conversation! Exclusive access to article comments.
